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 A Single Compound Alternative to a Buprenorphine/Naltrexone Combination, a functional 
kappa opioid receptor antagonist, produces antidepressant-like effects in mice.  
 
Abdulrahman M. Almatroudi, Stephen M. Husbands, Christopher P. Bailey and Sarah J. Bailey 
Department of Pharmacy and Pharmacology, University of Bath, UK.  
 
Introduction: Kappa-opioid receptor antagonists have a potential as novel antidepressants. However, 
they have a long lasting duration of action which potentially limits their use (Carroll and Carlezon 2013. 
J Med Chem 56: 2178-2195). Previously, we reported that buprenorphine/naltrexone (1mg/kg) 
combination produced a functional short-acting kappa-antagonist that was non-sedating, non-rewarding 
and produced antidepressant-like effects in mice. (Almatroudi et al. 2013. Proceedings of the British 
Pharmacological Society at https://bps.conference-
services.net/resources/344/3654/pdf/PHARM13_0127.pdf). Administration of buprenorphine and 
naltrexone as a single formulation is not achievable due to their different bioavailability, which could 
complicate patient compliance. Therefore, BU10119 was synthesized to have the pharmacological 
profile of the buprenorphine/naltrexone. Here, we report the effects of BU10119 treatment on 
depression-related behaviours. 
Methods: CD-1 male mice (8-10 weeks) were used. Injections were administered intraperitoneally (10 
ml/kg). Warm water (52°C) tail withdrawal assay was used to establish blockade of U50, 488 (10mg/kg) 
– induced antinociception by BU10119 (1 mg/kg) (n=5). For novelty-induced hypophagia (NIH), mice 
were individually housed and trained for 3 days to consume condensed milk. On test days, mice were 
injected with saline, buprenorphine/naltrexone combination (1 mg/kg), fluoxetine (20 mg/kg) or 
BU10119 (1mg/kg) one hour prior to testing behaviour (n=10). In the forced swim test (FST), a 6 min 
swim test session was recorded and behaviour scored manually (n=10). In the NIH test, the latency to 
drink and consumption were recorded in the home cage (day 4) and in the novel cage (day5). Data 
were analysed using a two-way repeated measures mixed model analysis or single measures one-way 
ANOVA (Invivostat 2.3).  
 
Results: BU10119 (1 m/kg) blocked the antinociceptive effects of U50, 488 (treatment*time F (12, 60) 
=12.57, p< 0.001). BU10119 significantly reduced tail withdrawal latency of U50 at 1, 8 and 24 h but not 
48 h (p< 0.001, p< 0.001, p< 0.01 and p=0.7). In the FST, there was a significant effect of drug-
treatment on swimming and immobility behaviours (swimming: F (3, 36) =6.58, P<0.001; immobility: F (3, 36) 
=7.02, P<0.001). Post-hoc testing revealed that fluoxetine, buprenorphine/naltrexone combination and 
BU10119 significantly reduced the time spent immobile, compared to controls (P<0.001). In the NIH 
test, there was a significant effect of drug treatment on the latency to drink in the novel cage (F (4, 45) 
=9.15, P<0.001) but not consumption (F (4, 45) =1.25, P=0.3). Fluoxetine, buprenorphine/naltrexone, 
norBNI (10 mg/kg) and BU10119 significantly reduced the latency to drink in the novel cage compared 
with controls (P<0.01).  
Conclusion: The BU10119 is a functional kappa-opioid receptor antagonist and produced 
antidepressant-like effects. 
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